Apolipoprotein ε2/3 genotype and type III hyperlipoproteinemia among Taiwanese

Clinica Chimica Acta

Volumn 330, Issue 1-2, 2003, Pages 173-178

  Lin, Hsing Pei ^a,b   Kao, Jau Tsuen ^a,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CATHAY GENERAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Apolipoprotein E; Coronary heart disease; Diabetes mellitus; Genotype; Polymerase chain reaction; Type III hyperlipoproteinemia

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ELECTROPHORESIS; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENOTYPE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; BLOOD; DNA SEQUENCE; GENETICS; MIDDLE AGED; PREVALENCE; TAIWAN;

AGED; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEINS E; ELECTROPHORESIS; FEMALE; GENOTYPE; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; LIPOPROTEINS; MALE; MIDDLE AGED; PREVALENCE; SEQUENCE ANALYSIS, DNA; TAIWAN; TRIGLYCERIDES;

EID: 0037375356     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(03)00050-0     Document Type: Article

References (36)

1. Bradley W.A., Gianturco S.H. ApoE is necessary and sufficient for the binding of large triglyceride-rich lipoproteins to the LDL receptor; apoB is unnecessary. J. Lipid Res. 27:1986;40-48.
2. Das H.K., McPherson J., Bruns G.A., Karathanasis S.K., Breslow J.L. Isolation, characterization, and mapping to chromosome 19 of the human apolipoprotein E gene. J. Biol. Chem. 260:1985;6240-6247.
3. Zannis V.I., Just P.W., Breslow J.L. Human apolipoprotein E isoprotein subclasses are genetically determined. Am. J. Hum. Genet. 33:1981;11-24.
4. Zannis V.I., Breslow J.L., Utermann G.et al. Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J. Lipid Res. 23:1982;911-914.
5. Weisgraber K.H., Rall S.C. Jr., Mahley R.W. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J. Biol. Chem. 256:1981;9077-9083.
6. Schneider W.J., Kovanen P.T., Brown M.S.et al. Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. J. Clin. Invest. 68:1981;1075-1085.
7. Gregg R.E., Zech L.A., Schaefer E.J., Brewer H.B. Jr. Type III hyperlipoproteinemia: defective metabolism of an abnormal apolipoprotein E. Science. 211:1981;584-586.
8. Mahley R.W., Rall S.C. Jr. Type III hyperlipoproteinemia: (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The metabolic and molecular bases of inherited disease. 7th ed. 1995;1953-1980 McGraw-Hill, New York, NY.
9. Davignon J., Gregg R.E., Sing C.F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 8:1988;1-21.
10. Rall S.C. Jr., Weisgraber K.H., Innerarity T.L., Bersot T.P., Mahley R.W., Blum C.B. Identification of a new structural variant of human apolipoprotein E, E2 (Lys146→Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype. J. Clin. Invest. 72:1983;1288-1297.
11. Havel R.J., Kotite L., Kane J.P., Tun P., Bersot T. Atypical familial dysbetalipoproteinemia associated with apolipoprotein phenotype E3/3. J. Clin. Invest. 72:1983;379-387.
12. Havekes L., de Wit E., Leuven J.G.et al. Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia. Hum. Genet. 73:1986;157-163.
13. Philadelphia (Glu13→Lys, Arg145→Cys). Homozygosity for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia. J. Biol. Chem. 266:1991;10479-10484.
14. Mann W.A., Gregg R.E., Sprecher D.L., Brewer H.B. Jr. Apolipoprotein E-1Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia. Biochim. Biophys. Acta. 1005:1989;239-244.
15. Brewer H.B. Jr., Zech L.A., Gregg R.E., Schwartz D., Schaefer E.J. NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. Ann. Intern. Med. 98:1983;623-640.
16. Lahiri D.K., Nurnberger J.I. Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 19:1991;5444.
17. Nobbs B.T., Smith J.M., Wallar A.W. Enzymic determination of plasma cholesterol on discrete automatic analyzers. Clin. Chim. Acta. 79:1977;391-397.
18. Naito H.K., Gatautis V.J., Galen R.S. The measurement of serum triglyceride on the Hitachi 705 chemistry analyzer. Clin. Chem. 31:1985;948.
19. Lopes-Virella M.F., Stone P., Ellis S., Colwell J.A. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin. Chem. 23:1977;882-884.
20. Nauck M., Glatt L., Marz W., Feussner G., Wieland H. Simple precipitation-based method for the screening of type III hyperlipoproteinemia. Clin. Chem. 45:1999;909-911.
21. Richard P., Thomas G., de Zulueta M.P.et al. Common and rare genotypes of human apolipoprotein E determined by specific restriction profiles of polymerase chain reaction-amplified DNA. Clin. Chem. 40:1994;24-29.
22. Feussner G., Wagner A., Kohl B., Ziegler R. Clinical features of type III hyperlipoproteinemia: analysis of 64 patients. Clin. Invest. 71:1993;362-366.
23. Eto M., Saito M., Nakata H.et al. Type III hyperlipoproteinema with apolipoprotein E2/2 genotype in Japan. Clin. Genet. 61:2002;416-422.
24. Breslow J.L., Zannis V.I., SanGiacomo T.R., Third J.L., Tracy T., Glueck C.J. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. J. Lipid Res. 23:1982;1224-1235.
25. Klasen E.C., Talmud P.J., Havekes L.et al. A common restriction fragment length polymorphism of the human apolipoprotein E gene and its relationship to type III hyperlipidaemia. Hum. Genet. 75:1987;244-247.
26. Civeira F., Pocovi M., Cenarro A.et al. Apo E variants in patients with type III hyperlipoproteinemia. Atherosclerosis. 127:1996;273-282.
27. Feussner G., Feussner V., Hoffmann M.M., Lohrmann J., Wieland H., Marz W. Molecular basis of type III hyperlipoproteinemia in Germany. Hum. Mutat. 11:1998;417-423.
28. Kitahara M., Shinomiya M., Shirai K., Saito Y., Yoshida S. Frequency and role of apo E phenotype in familial hypercholesterolemia and non-familial hyperlipidemia in the Japanese. Atherosclerosis. 82:1990;197-204.
29. Kao J.T., Tsai K.S., Chang C.J., Huang P.C. The effects of apolipoprotein E polymorphism on the distribution of lipids and lipoproteins in the Chinese population. Atherosclerosis. 114:1995;55-59.
30. Dallongeville J., Lussier-Cacan S., Davignon J. Modulation of plasma triglyceride concentrations by apoE phenotype: a meta-analysis. J. Lipid Res. 33:1992;447-454.
31. Hopkins P.N., Wu L.L., Schumacher M.C.et al. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction. Arterioscler. Thromb. 11:1991;1137-1146.
32. Haffner S.M., Kushwaha R.S., Hazzard W.R. Metabolism of apolipoprotein B in members of a family with accelerated atherosclerosis: influence of apolipoprotein E-3/E-2 pattern. Metabolism. 41:1992;241-245.
33. de Knijff P., van den Maagdenberg A.M., Stalenhoef A.F.et al. Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree. J. Clin. Invest. 88:1991;643-655.
34. de Knijff P., van den Maagdenberg A.M., Boomsma D.I.et al. Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146→Gln) Allele carriers. J. Clin. Invest. 94:1994;1252-1262.
35. de Villiers W.J., van der Westhuyzen D.R., Coetzee G.A., Henderson H.E., Marais A.D. The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance. Arterioscler. Thromb. Vasc. Biol. 17:1997;865-872.
36. Suehiro T., Yoshida K., Yamano T., Ohno F. Identification and characterization of a new variant of apolipoprotein E (apo E-Kochi). Jpn. J. Med. 29:1990;587-594.